StreetInsider.com News Articles

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: Foust Warren

Tue, 18 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26944094.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: Foust Warren

Tue, 18 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26944094.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: ANDREWS DEBORAH J

Tue, 18 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26944095.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: ANDREWS DEBORAH J

Tue, 18 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26944095.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: Michna Magda

Tue, 18 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26944098.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: Michna Magda

Tue, 18 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26944098.html

STAAR Surgical (STAA) PT Lowered to $28 at Stifel After Net-Positive Earnings Call

Mon, 17 Aug 2026 07:02:08 -0400

Stifel analyst Thomas M. Stephan lowered the price target on STAAR Surgical (NASDAQ: STAA) to $28.00 (from $31.00) while maintaining a Hold rating.

The analyst commented, "The updates from the earnings call (which follow the mid-July pre-announcement) were net-positive, in our view—highlighted by China share gains, encouraging China trends (contrary to cautious commentary from competitors), EVO+ momentum, and solid EBITDA. Importantly, the company appears comfortable with Street’s low-$80M 3Q26 revenue estimate and ~$335M FY26 figure—although the lack of formal guidance may continue to frustrate investors and add to uncertainty about how “real” the China rebound is. The 2H26 setup appears positive,

STAAR Surgical (STAA) PT Lowered to $28 at Stifel After Net-Positive Earnings Call

Mon, 17 Aug 2026 07:02:08 -0400

Stifel analyst Thomas M. Stephan lowered the price target on STAAR Surgical (NASDAQ: STAA) to $28.00 (from $31.00) while maintaining a Hold rating.

Form SCHEDULE 13G/A STAAR SURGICAL CO Filed by: Madison Avenue Partners, LP

Fri, 14 Aug 2026 10:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26926107.html

Form SCHEDULE 13G/A STAAR SURGICAL CO Filed by: Madison Avenue Partners, LP

Fri, 14 Aug 2026 10:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26926107.html

STAAR Surgical (STAA) PT Lowered to $28 at Jefferies

Thu, 13 Aug 2026 16:05:32 -0400

Jefferies analyst Young Li lowered the price target on STAAR Surgical (NASDAQ: STAA) to $28.00 (from $29.00) while maintaining a Hold rating.

The analyst comments "STAA reported 2Q26 revs of $93.5 MM (flat qoq), a 4% beat vs cons, driven by China sales of $52.3 MM (+10% qoq) on share gains, EVO+ adoption, and higher ASPs. GM of 74.5% and EBITDA of 21.4% beat cons by 60 bps and 205 bps, respectively, while EPS of 16c missed cons of 22c. STAA provided some incremental color on the 2H but still haven't issued guidance. We are updating estimates, lowering PT to $28,

STAAR Surgical (STAA) PT Lowered to $28 at Jefferies

Thu, 13 Aug 2026 16:05:32 -0400

Jefferies analyst Young Li lowered the price target on STAAR Surgical (NASDAQ: STAA) to $28.00 (from $29.00) while maintaining a Hold rating.

Piper Sandler on STAAR Surgical (STAA): 'We Remain On The Sidelines'

Thu, 13 Aug 2026 09:25:08 -0400

Piper Sandler analyst Adam C. Maeder reiterated a Neutral rating and $33.00 price target on STAAR Surgical (NASDAQ: STAA).

The analyst commented: "Solid Q2 China Performance; Mixed Update Ex-China; We Remain On The Sidelines; STAA reported Q2 results this evening which were consistent with the company's 7/16 preannouncement and beat our/Street's expectations on both the top and bottom-line. The China business ($52.3M) was the bright spot in the quarter and led the majority of the topline beat, coming in better than Street ($49.6M), with mgmt. highlighting that it is continuing to take share, although it is unclear to us how much

STAAR Surgical (STAA) PT Lowered to $19 at UBS

Thu, 13 Aug 2026 09:15:45 -0400

UBS analyst Patrick Wood lowered the price target on STAAR Surgical (NASDAQ: STAA) to $19.00 (from $20.00) while maintaining a Sell rating.

Form 10-Q STAAR SURGICAL CO For: Jul 03

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912802.html

Form 10-Q STAAR SURGICAL CO For: Jul 03

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912802.html

Form 8-K STAAR SURGICAL CO For: Aug 12

Wed, 12 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26912688.html

Form 8-K STAAR SURGICAL CO For: Aug 12

Wed, 12 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26912688.html

STAAR Surgical (STAA) Tops Q2 EPS by 2c, Beats on Revenue

Wed, 12 Aug 2026 16:02:35 -0400

STAAR Surgical (NASDAQ: STAA) reported Q2 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $93.5 million versus the consensus estimate of $90.17 million.

For earnings history and earnings-related data on STAAR Surgical (STAA) click here.

STAAR Surgical Reports Second Quarter 2026 Results

Wed, 12 Aug 2026 16:01:00 -0400

Net Sales of $93.5 million, up 111% Y/Y

Net Income of $8.1 million, with GAAP EPS of $0.16

Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share

Earnings Call and Webcast Today at 5:30 PM Eastern

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended July 3, 2026.

Second Quarter 2026 Financial Overview

Net sales of $93.5 million, up 111% Y/Y
Net sales excluding China of $41.2 million, up 6.0%

STAAR Surgical Reports Second Quarter 2026 Results

Wed, 12 Aug 2026 16:01:00 -0400

Net Sales of $93.5 million, up 111% Y/Y

Net Income of $8.1 million, with GAAP EPS of $0.16

Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share

Earnings Call and Webcast Today at 5:30 PM Eastern

Second Quarter 2026 Financial Overview

Net sales of $93.5 million, up 111% Y/Y
Net sales excluding China of $41.2 million, up 6.0%

STAAR Surgical Reports Second Quarter 2026 Results

Wed, 12 Aug 2026 16:01:00 -0400

Net Sales of $93.5 million, up 111% Y/Y

Net Income of $8.1 million, with GAAP EPS of $0.16

Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share

Earnings Call and Webcast Today at 5:30 PM Eastern

Second Quarter 2026 Financial Overview

Net sales of $93.5 million, up 111% Y/Y
Net sales excluding China of $41.2 million, up 6.0%

STAAR Surgical Reports Second Quarter 2026 Results

Wed, 12 Aug 2026 16:01:00 -0400

Net Sales of $93.5 million, up 111% Y/Y

Net Income of $8.1 million, with GAAP EPS of $0.16

Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share

Earnings Call and Webcast Today at 5:30 PM Eastern

Second Quarter 2026 Financial Overview

Net sales of $93.5 million, up 111% Y/Y
Net sales excluding China of $41.2 million, up 6.0%

STAAR Surgical Reports Second Quarter 2026 Results

Wed, 12 Aug 2026 16:01:00 -0400

Net Sales of $93.5 million, up 111% Y/Y

Net Income of $8.1 million, with GAAP EPS of $0.16

Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share

Earnings Call and Webcast Today at 5:30 PM Eastern

Second Quarter 2026 Financial Overview

Net sales of $93.5 million, up 111% Y/Y
Net sales excluding China of $41.2 million, up 6.0%

STAAR Surgical Reports Second Quarter 2026 Results

Wed, 12 Aug 2026 16:01:00 -0400

Net Sales of $93.5 million, up 111% Y/Y

Net Income of $8.1 million, with GAAP EPS of $0.16

Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share

Earnings Call and Webcast Today at 5:30 PM Eastern

Second Quarter 2026 Financial Overview

Net sales of $93.5 million, up 111% Y/Y
Net sales excluding China of $41.2 million, up 6.0%